Thomas Heinemann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Heinemann has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Tobias Cantz
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany
4 shared publications - Hans-Georg Dederer
Universität Passau
3 shared publications - Jan Schnalke
Institute for Medical Humanities, Medical Faculty, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
2 shared publications - Johanna Risse
Institute for Medical Humanities, Medizinische Fakultät, Universitätsklinikum Bonn Bonn Germany
2 shared publications Anke Schulze
CellAct Pharma GmbH, Berlin, Germany
1 shared publicationBarbara Advena‐Regnery
1 shared publication
Latest Publications
- 29 August 2025
- Published by Walter de Gruyter GmbH in Zeitschrift für medizinische Ethik
- Vol. 71 (3) , 342-367
Somatische genomische Therapien als Paradigma für individualisierte Behandlungen
Neuartige CRISPR/Cas-Verfahren zur präzisen Manipulation des Genoms eröffnen das Feld der somatischen genomischen Therapien. Diese ermöglichen individualisierte Behandlungen, die als solche nicht nach etablierten Standards vorab auf Wirkung und Risiken geprüft werden können. Somit wird fraglich, ob sie vorrangig als therapeutische oder als Forschungshandlungen ethisch zu bewerten sind, mit Folgen u.a. für die Kriterien der Sicherheit und Zugangsgerechtigkeit. Ähnliche Fragen sind auch für zukünftige individualisierte Behandlungen weit verbreiteter Erkrankungen zu beachten.
- 29 August 2025
- Published by Walter de Gruyter GmbH in Zeitschrift für medizinische Ethik
- Vol. 71 (3) , 342-367
Somatische genomische Therapien als Paradigma für individualisierte Behandlungen
Neuartige CRISPR/Cas-Verfahren zur präzisen Manipulation des Genoms eröffnen das Feld der somatischen genomischen Therapien. Diese ermöglichen individualisierte Behandlungen, die als solche nicht nach etablierten Standards vorab auf Wirkung und Risiken geprüft werden können. Somit wird fraglich, ob sie vorrangig als therapeutische oder als Forschungshandlungen ethisch zu bewerten sind, mit Folgen u.a. für die Kriterien der Sicherheit und Zugangsgerechtigkeit. Ähnliche Fragen sind auch für zukünftige individualisierte Behandlungen weit verbreiteter Erkrankungen zu beachten.
- Open Access
- 29 August 2025
- Published by Walter de Gruyter GmbH in Zeitschrift für medizinische Ethik
- Vol. 71 (3) , 277-278
Neue „somatische genomische Therapien“
"Neue „somatische genomische Therapien“" published on 29 Aug 2025 by Brill | mentis.
- 29 August 2025
- Published by Walter de Gruyter GmbH in Zeitschrift für medizinische Ethik
- Vol. 71 (3) , 277-278
Open AccessNeue „somatische genomische Therapien“
"Neue „somatische genomische Therapien“" published on 29 Aug 2025 by Brill | mentis.
- Open Access
- 11 August 2025
- Published by Springer Nature in Medicine, Health Care and Philosophy
- Vol. 28 (3) , 425-445
“Snip, snip, cure”? Philosophical, legal and biomedical perspectives on novel somatic genomic therapies
The advent of innovative techniques, such as the CRISPR/Cas system, has opened up a new range of possibilities for modifying the genome, with the potential to address previously unmet therapeutic needs of patients with genetic diseases. These new possibilities have not only raised ethical concerns but also challenged existing classifications of genome modification techniques. While the legal status of some of these new therapies remains uncertain, there is an ongoing debate within philosophy of biology about the information-related metaphors adopted by scientists to describe and classify the genome and its therapeutic modification. Given the continuing advance of new genomic therapies, we show, employing an interdisciplinary approach, that a comprehensive framework for the classification of these technologies is needed to resolve legal and philosophical issues. The first section provides an analysis of the current state of novel genome-modifying techniques in medical genetics. In the second section, we assess the regulatory status of these techniques within the European regulatory framework for advanced therapy medicinal products (ATMPs). Drawing on these results, we argue in the third section from a philosophical perspective that metaphors, such as ‘editing’ the genome, which are based on a conception of the genome as linear information, cannot adequately capture the breadth of advanced genomic technologies. To accurately categorise these techniques in a manner that meets their diverse applications, we propose introducing the umbrella term ‘somatic genomic therapies’ (SGTs). Urging an integrative approach to defining and classifying new technologies in medical genetics, we advocate for the development of an integrative concept of SGTs.
- 11 August 2025
- Published by Springer Nature in Medicine, Health Care and Philosophy
- Vol. 28 (3) , 425-445
Open Access“Snip, snip, cure”? Philosophical, legal and biomedical perspectives on novel somatic genomic therapies
The advent of innovative techniques, such as the CRISPR/Cas system, has opened up a new range of possibilities for modifying the genome, with the potential to address previously unmet therapeutic needs of patients with genetic diseases. These new possibilities have not only raised ethical concerns but also challenged existing classifications of genome modification techniques. While the legal status of some of these new therapies remains uncertain, there is an ongoing debate within philosophy of biology about the information-related metaphors adopted by scientists to describe and classify the genome and its therapeutic modification. Given the continuing advance of new genomic therapies, we show, employing an interdisciplinary approach, that a comprehensive framework for the classification of these technologies is needed to resolve legal and philosophical issues. The first section provides an analysis of the current state of novel genome-modifying techniques in medical genetics. In the second section, we assess the regulatory status of these techniques within the European regulatory framework for advanced therapy medicinal products (ATMPs). Drawing on these results, we argue in the third section from a philosophical perspective that metaphors, such as ‘editing’ the genome, which are based on a conception of the genome as linear information, cannot adequately capture the breadth of advanced genomic technologies. To accurately categorise these techniques in a manner that meets their diverse applications, we propose introducing the umbrella term ‘somatic genomic therapies’ (SGTs). Urging an integrative approach to defining and classifying new technologies in medical genetics, we advocate for the development of an integrative concept of SGTs.
- Open Access
- 24 April 2024
- Published by Springer Nature in Gene Therapy
- Vol. 31 (7-8) , 353-357
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
An increasing number of novel genomic therapies are expected to become available for patients with rare or ultra-rare diseases. However, the primary obstacle to equal patient access to these orphan genomic therapies are currently very high prices charged by manufacturers in the context of limited healthcare budgets. Taking into account ethical pricing theories, the paper proposes the implementation of a pricing infrastructure covering all European member states, which has the potential to promote distributive justice while maintaining the attractiveness of genomic therapy development.
- 24 April 2024
- Published by Springer Nature in Gene Therapy
- Vol. 31 (7-8) , 353-357
Open AccessTowards ethical drug pricing: the European Orphan Genomic Therapies Fund
An increasing number of novel genomic therapies are expected to become available for patients with rare or ultra-rare diseases. However, the primary obstacle to equal patient access to these orphan genomic therapies are currently very high prices charged by manufacturers in the context of limited healthcare budgets. Taking into account ethical pricing theories, the paper proposes the implementation of a pricing infrastructure covering all European member states, which has the potential to promote distributive justice while maintaining the attractiveness of genomic therapy development.
- Open Access
- 11 September 2020
- Published by Springer Nature in BMC Medical Ethics
- Vol. 21 (1) , 1-12
Human germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy
Background: Clustered Regularly Interspaced Short Palindromic Repeats-associated (CRISPR-Cas) technology may allow for efficient and highly targeted gene editing in single-cell embryos. This possibility brings human germline editing into the focus of ethical and legal debates again. Main body: Against this background, we explore essential ethical and legal questions of interventions into the human germline by means of CRISPR-Cas: How should issues of risk and uncertainty be handled? What responsibilities arise regarding future generations? Under which conditions can germline editing measures be therapeutically legitimized? For this purpose, we refer to a scenario anticipating potential further development in CRISPR-Cas technology implying improved accuracy and exclusion of germline transmission to future generations. We show that, if certain concepts regarding germline editing are clarified, under such conditions a categorical prohibition of one-generation germline editing of single-cell embryos appears not to be ethically or legally justifiable. Conclusion: These findings are important prerequisites for the international debate on the ethical and legal justification of germline interventions in the human embryo as well as for the harmonization of international legal standards.
- 11 September 2020
- Published by Springer Nature in BMC Medical Ethics
- Vol. 21 (1) , 1-12
Open AccessHuman germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy
Background: Clustered Regularly Interspaced Short Palindromic Repeats-associated (CRISPR-Cas) technology may allow for efficient and highly targeted gene editing in single-cell embryos. This possibility brings human germline editing into the focus of ethical and legal debates again. Main body: Against this background, we explore essential ethical and legal questions of interventions into the human germline by means of CRISPR-Cas: How should issues of risk and uncertainty be handled? What responsibilities arise regarding future generations? Under which conditions can germline editing measures be therapeutically legitimized? For this purpose, we refer to a scenario anticipating potential further development in CRISPR-Cas technology implying improved accuracy and exclusion of germline transmission to future generations. We show that, if certain concepts regarding germline editing are clarified, under such conditions a categorical prohibition of one-generation germline editing of single-cell embryos appears not to be ethically or legally justifiable. Conclusion: These findings are important prerequisites for the international debate on the ethical and legal justification of germline interventions in the human embryo as well as for the harmonization of international legal standards.
- Open Access
Framing the ethical and legal issues of human artificial gametes in research, therapy, and assisted reproduction: A German perspective
Recent results from studies on animals suggest that functional germ cells may be generated from human pluripotent stem cells, giving rise to three possibilities: research with these so‐called artificial gametes, including fertilization experiments in vitro; their use in vivo for therapy for the treatment of human infertility; and their use in assisted reproductive technologies in vitro. While the legal, philosophical, and ethical questions associated with these possibilities have been already discussed intensively in other countries, the debate in Germany is still at its beginning. A systematic and detailed analysis of the legal framework in Germany is provided with regard to the three possibilities, including the applicable statutory laws as well as the constitutional law. The question emerges as to whether the statutory laws as well as the constitution justify a distinction to be made between embryos of artificial and natural origin. This question is subject to philosophical analysis, discussing the distinction between person and thing, dignity and price, personality and property, and nature and technique. As a result, the criterion of naturalness alone may not be sufficient to differentiate between embryos of natural and artificial origin, and other criteria need to be identified.
Open AccessFraming the ethical and legal issues of human artificial gametes in research, therapy, and assisted reproduction: A German perspective
Recent results from studies on animals suggest that functional germ cells may be generated from human pluripotent stem cells, giving rise to three possibilities: research with these so‐called artificial gametes, including fertilization experiments in vitro; their use in vivo for therapy for the treatment of human infertility; and their use in assisted reproductive technologies in vitro. While the legal, philosophical, and ethical questions associated with these possibilities have been already discussed intensively in other countries, the debate in Germany is still at its beginning. A systematic and detailed analysis of the legal framework in Germany is provided with regard to the three possibilities, including the applicable statutory laws as well as the constitutional law. The question emerges as to whether the statutory laws as well as the constitution justify a distinction to be made between embryos of artificial and natural origin. This question is subject to philosophical analysis, discussing the distinction between person and thing, dignity and price, personality and property, and nature and technique. As a result, the criterion of naturalness alone may not be sufficient to differentiate between embryos of natural and artificial origin, and other criteria need to be identified.
- Open Access
- 13 February 2008
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (2) , e1576
HLA-DR Alpha 2 Mediates Negative Signalling via Binding to Tirc7 Leading to Anti-Inflammatory and Apoptotic Effects in Lymphocytes In Vitro and In Vivo
Classically, HLA-DR expressed on antigen presenting cells (APC) initiates lymphocyte activation via presentation of peptides to TCR bearing CD4+ T-Cells. Here we demonstrate that HLA-DR alpha 2 domain (sHLA-DRα2) also induces negative signals by engaging TIRC7 on lymphocytes. This interaction inhibits proliferation and induces apoptosis in CD4+ and CD8+ T-cells via activation of the intrinsic pathway. Proliferation inhibition is associated with SHP-1 recruitment by TIRC7, decreased phosphorylation of STAT4, TCR-ζ chain & ZAP70, and inhibition of IFN-γ and FasL expression. HLA-DRα2 and TIRC7 co-localize at the APC-T cell interaction site. Triggering HLA-DR - TIRC7 pathway demonstrates that sHLA-DRα2 treatment inhibits proinflammatory-inflammatory cytokine expression in APC & T cells after lipopolysaccaride (LPS) stimulation in vitro and induces apoptosis in vivo. These results suggest a novel antiproliferative role for HLA-DR mediated via TIRC7, revise the notion of an exclusive stimulatory interaction of HLA-DR with CD4+ T cells and highlights a novel physiologically relevant regulatory pathway.
- 13 February 2008
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (2) , e1576
Open AccessHLA-DR Alpha 2 Mediates Negative Signalling via Binding to Tirc7 Leading to Anti-Inflammatory and Apoptotic Effects in Lymphocytes In Vitro and In Vivo
Classically, HLA-DR expressed on antigen presenting cells (APC) initiates lymphocyte activation via presentation of peptides to TCR bearing CD4+ T-Cells. Here we demonstrate that HLA-DR alpha 2 domain (sHLA-DRα2) also induces negative signals by engaging TIRC7 on lymphocytes. This interaction inhibits proliferation and induces apoptosis in CD4+ and CD8+ T-cells via activation of the intrinsic pathway. Proliferation inhibition is associated with SHP-1 recruitment by TIRC7, decreased phosphorylation of STAT4, TCR-ζ chain & ZAP70, and inhibition of IFN-γ and FasL expression. HLA-DRα2 and TIRC7 co-localize at the APC-T cell interaction site. Triggering HLA-DR - TIRC7 pathway demonstrates that sHLA-DRα2 treatment inhibits proinflammatory-inflammatory cytokine expression in APC & T cells after lipopolysaccaride (LPS) stimulation in vitro and induces apoptosis in vivo. These results suggest a novel antiproliferative role for HLA-DR mediated via TIRC7, revise the notion of an exclusive stimulatory interaction of HLA-DR with CD4+ T cells and highlights a novel physiologically relevant regulatory pathway.